Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2012

View Archived Issues

Novel acetyl-CoA carboxylase 2 inhibitors presented

Taisho reports novel phosphodiesterase 10A inhibitors

Janssen discloses new serotonin 5-HT2B receptor antagonists

Data presented from TRACER and TRAP2P-TIMI 50 vorapaxar trials

Immunotherapy potently reduces LDL cholesterol in phase I trials

Transient receptor potential TRPV1 channel antagonist well tolerated in healthy volunteers

PharmaNeuroBoost clear to commence proof-of-concept PNB-02 trial

Omadacycline noninferior to linezolid in phase III trial

Shionogi and OncoTherapy Science expand licensing agreement

Allergan obtains rights for Ameluz in Spain

ImmunoGen begins phase II IMGN-901 study

Preclinical data support entry of ABTL-0812 into the clinic

ViroMed clear to conduct head-to-head phase III VM-501 study

Roche reports topline data from phase III EMILIA trial

TH-302 gets orphan drug status in E.U. and U.S.

Myriad Genetics and Cephalon enter agreement for mutation testing in phase I/II study

Cardium Therapeutics launches wound care product in U.S.

Portola begins pivotal study of its factor Xa inhibitor

Kyowa Hakko Kirin files application for approval of Parkinson's disease treatment in Japan

Roche divulges novel HDL cholesterol-increasing agents

Novel GCS activators patented by Bayer Schering

First three phase III QVA-149 studies meet primary endpoints

GSK seeks Japanese approval for combination tablet to prevent and treat malaria

Minophagen granted additional rights to bexarotene

Novartis seeks approval for Lucentis line extension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...